Closing The Gap Between Biomarker Data And Clinical Proof-Of-Mechanism In Neurodegenerative Disease

Demonstrating that a central nervous system therapy successfully reaches its target and drives biological change remains a significant hurdle in neurodegenerative drug development. Overcoming this barrier requires aligning translational clinical pharmacology, targeted bioanalysis, and fit-for-purpose biomarker strategies early in the development pipeline. Utilizing a question-based framework allows sponsors to establish a clear chain of evidence—from exposure and target engagement to downstream pathway modulation. Selecting context-appropriate clinical models, optimizing sampling designs, and applying validated biomarker assays provide the robust data needed to make decisive early-phase transitions. Real-world applications involving glucocerebrosidase (GCase) and lipid biomarkers demonstrate how rapid bioanalytical turnaround and precise measurement reduce risk and strengthen confidence in proof-of-mechanism.

Access the full webinar to discover actionable strategies for closing the gap between biomarker data and clinical proof.